Marcel Walther

Marcel Walther

Auto-generated profile, based on publicly available information

Marcel Walther

Institute of Pharmaceutical Technology and Buchmann Institute for Molecular Life Sciences Goethe University Frankfurt Max-von-Laue-Str. 9 60438 Frankfurt am Main Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2022 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
MWMarcel Walther
Marcel Walther
PVPia Katharina Vestweber
Pia Katharina Vestweber
SKShafreena Kühn
Shafreena Kühn
URUlrich Rieger
Ulrich Rieger
JSJasmin Schäfer
Jasmin Schäfer
MWMaike Windbergs
Maike Windbergs

20 September 2022 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
TKTobias Kielholz
Tobias Kielholz
MWMarcel Walther
Marcel Walther
NJNathalie Jung
Nathalie Jung
MWMaike Windbergs
Maike Windbergs

27 January 2023 in Advanced NanoBiomed Research
Verified
Journal Article
Open access
FRFelix Rohde
Felix Rohde
MWMarcel Walther
Marcel Walther
FBFlorentin Baur
Florentin Baur
MWMaike Windbergs
Maike Windbergs
Tissue transplantations are often associated with severe infections. Cornea replacement as the most frequent transplantation worldwide bears the risk of keratitis caused by herpes simplex virus (HSV), posing a severe and sight‐threatening complication. To overcome the current lack of effective HSV therapy in the eye, biodegradable nanofibrous scaffolds incorporating acyclovir (ACV) intended for transplantation along with the cornea graft to prevent viral infections are designed. The rational development of these matrices reveals the strong dependency of the surface wettability on the release kinetics of the tested biocompatible poly(lactic‐co‐glycolic acid) (PLGA) polymers. Using a mixture of two PLGA polymers, a tailor‐made release of the antiviral active ACV is achieved for the intended treatment period. In a human in vitro HSV infection model, a synergistic viral inhibition mechanism by binding the virus particles on the fibers surface, while simultaneously releasing the antiviral active, could be confirmed. Besides the controlled ACV release, the polymer fibers bind virus particles to their surface, significantly reducing the virus titer. Based on this tunable dual effect, the fiber scaffolds exhibit a promising antiviral drug delivery platform, which can overcome the limitations of current infection therapy associated with cornea transplantation.